HUP2000379A1 - Pharmaceutical composition comprising favipiravir, production and use thereof - Google Patents

Pharmaceutical composition comprising favipiravir, production and use thereof

Info

Publication number
HUP2000379A1
HUP2000379A1 HU2000379A HUP2000379A HUP2000379A1 HU P2000379 A1 HUP2000379 A1 HU P2000379A1 HU 2000379 A HU2000379 A HU 2000379A HU P2000379 A HUP2000379 A HU P2000379A HU P2000379 A1 HUP2000379 A1 HU P2000379A1
Authority
HU
Hungary
Prior art keywords
favipiravir
production
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
HU2000379A
Other languages
Hungarian (hu)
Inventor
Fekete Pala Dr
Nacsa Fruzsina Dr
Gal Livia Dr
Zsolt Oeszi
Original Assignee
Meditop Gyogyszeripari Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meditop Gyogyszeripari Kft filed Critical Meditop Gyogyszeripari Kft
Priority to HU2000379A priority Critical patent/HUP2000379A1/en
Priority to PCT/HU2021/050062 priority patent/WO2022106859A1/en
Publication of HUP2000379A1 publication Critical patent/HUP2000379A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU2000379A 2020-11-17 2020-11-17 Pharmaceutical composition comprising favipiravir, production and use thereof HUP2000379A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HU2000379A HUP2000379A1 (en) 2020-11-17 2020-11-17 Pharmaceutical composition comprising favipiravir, production and use thereof
PCT/HU2021/050062 WO2022106859A1 (en) 2020-11-17 2021-11-17 Pharmaceutical preparation containing favipiravir, its production and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU2000379A HUP2000379A1 (en) 2020-11-17 2020-11-17 Pharmaceutical composition comprising favipiravir, production and use thereof

Publications (1)

Publication Number Publication Date
HUP2000379A1 true HUP2000379A1 (en) 2022-05-28

Family

ID=89993232

Family Applications (1)

Application Number Title Priority Date Filing Date
HU2000379A HUP2000379A1 (en) 2020-11-17 2020-11-17 Pharmaceutical composition comprising favipiravir, production and use thereof

Country Status (2)

Country Link
HU (1) HUP2000379A1 (en)
WO (1) WO2022106859A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2407166T1 (en) * 2009-03-13 2013-12-31 Toyama Chemical Co., Ltd. Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
JP7163014B2 (en) * 2016-10-31 2022-10-31 エスエス製薬株式会社 cold medicine
RU2731932C1 (en) * 2020-05-07 2020-09-09 Общество с ограниченной ответственностью "Кромис" (ООО "Кромис") Anti-covid-19 (sars-cov-2) viral pharmaceutical composition

Also Published As

Publication number Publication date
WO2022106859A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
GB202019241D0 (en) Pharmaceutical composition
IL311331A (en) Pharmaceutical composition and use thereof
EP4183391A4 (en) Pharmaceutical composition and use thereof
IL312874A (en) Pharmaceutical composition and use thereof
EP4223759A4 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
EP3950677A4 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
GB2568928B (en) Neuroprotective composition, preparation process thereof and medical uses thereof
HUP2000379A1 (en) Pharmaceutical composition comprising favipiravir, production and use thereof
IL284132A (en) Pharmaceutical compound, the method of its making and use as medicinal agent
EP4071170A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
EP3733176A4 (en) Composition comprising piperacillin, pharmaceutical preparation thereof and use thereof
EP3718543A4 (en) Pharmaceutical composition and use thereof
GB202004832D0 (en) Therapeutic agaents, pharmaceutical compositions, and associated biomarkers
HUP2200422A1 (en) Stubble-decomposing microbiological composition, its production and use thereof
GB202117015D0 (en) New pharmaceutical composition
GB202117007D0 (en) New pharmaceutical composition
GB202117005D0 (en) New pharmaceutical composition
EP4139275A4 (en) Compounds and pharmaceutical uses thereof
GB202018901D0 (en) New pharmaceutical composition
GB202009905D0 (en) New pharmaceutical composition
GB202007328D0 (en) New pharmaceutical composition
GB202007306D0 (en) New pharmaceutical composition
EP4125873A4 (en) Pharmaceutical compositions and use thereof
GB202113078D0 (en) New pharmaceutical use
EP4108236A4 (en) Olaparib pharmaceutical composition, preparation thereof, preparation method therefor and use thereof